Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 671800 ED versus montelukast, fluticasone, and placebo in seasonal allergic rhinitis using an environmental challenge chamber
2009-013269-24Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of BI-671800 in seasonal allergic rhinitis (SAR) and allergic rhinitis (AR) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Total Nasal Symptom Score area under the curve from 0 to 6 hours. Started Sep 2009; status: completed.
02
Drugs
BI-671800
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2009-013269-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013269-24.